Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
doesn't move fast but next leg is in the works
INIS beautiful weekly break out in the works
nice close...selling in the morning
Nice, Just wish I filled more at my avg, wont be adding more
listen to the chart...more to come
Booooom! Why didn't I buy more lol never good at listening to myself
INIS really great PR just over a wk ago, major sleeper here, I will be buying shares on dips
International Isotopes Inc. Provides Shareholders With An Update On New Opportunities And Positive Developments Within Its Existing Business Segments PR Newswire "Press Releases US - English"
IDAHO FALLS, Idaho , April 20, 2015 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS, or the "Company") is pleased to provide shareholders with the following update on its business segments.
Cobalt Products
Historically, INIS has produced and sold high-activity cobalt which is used to fabricate several models of sealed sources for medical and industrial applications. These products include applications such as radiation therapy, security examination, and radiography. Due to technical issues at the Department of Energy's (DOE) Advanced Test Reactor (ATR) during 2012, that were unrelated to INIS, we were forced to discontinue irradiation of cobalt targets. Since that time, INIS has been working closely with the DOE to resolve those issues. We are pleased to report that in October 2014 , we were able to sign a new ten-year cobalt production agreement with the DOE utilizing a new cobalt target design. This agreement gives INIS access to all currently available cobalt production positions in the ATR, thereby making INIS the exclusive cobalt supplier from this or any other DOE reactor in the U.S. Globally, there are only a few reactors capable of producing high activity cobalt.
Since the October 2014 agreement was completed with the DOE, we have been in contract negotiations with several customers that were expected to commit to purchasing most of the cobalt that the ATR reactor will produce under our DOE agreement. We are pleased to report that INIS has entered into contracts for the sale of most of the bulk cobalt the ATR will produce. INIS has also reserved an adequate amount of the ATR cobalt for its own use for sealed source manufacture. Although each of the Company's cobalt contracts are slightly different, the terms of all contracts stipulate quarterly progress payments to INIS during the cobalt irradiation cycle, each of which will run two to three years. INIS has received initial down payments from each customer which in the aggregate exceed one million dollars .
Pharmaceuticals and Radiopharmaceuticals
For the past few years, INIS has been developing several new generic radiopharmaceutical products that we plan to submit to the U.S. Food and Drug Administration (FDA) for approval. These products are in various stages of manufacturing development or of the FDA application process. Although these products are generics, we believe each will serve an important niche in the market that we feel is currently underserved. The first of these products is nearing completion of its preparation for an Abbreviated New Drug Application (ANDA) which should be submitted to the FDA around year-end or in early 2016. We believe that the other ANDAs will follow later in 2016. We would like to stress that there can be no assurances that the Company will successfully complete all the development, testing, and submittals required by the FDA. The FDA review process is rigorous and is likely to last fifteen to twenty four months or longer with no guarantee of approval.
Hobbs, NM De-conversion Project
The build-out of the Hobbs, NM uranium hexafluoride de-conversion plant remains contingent upon securing contracts for the throughput of the plant. The 2011 tsunami that struck Japan and low natural gas prices, together, have slowed the progress of nuclear projects globally, including the various enrichment plants that were planned to be built in the US. Those plants were expected to be sources of feed for our facility in NM. We are still in active negotiations regarding the plant, but while we remain optimistic, at the present time we cannot predict if or when the plant will be built. The 40 year operating license that we have secured from the NRC is not impacted by our delayed start of construction. Further, we have continued to meet with the various government entities in Lea County, NM , who put the incentive package together for us to locate there. We continue to work with them to negotiate an extension to that incentive package, including the 660 acres of land where the facility is planned to be sited.
Steve Laflin , President and CEO commented, "While the Hobbs de-conversion project remains on hold, we are continuing to diligently build a solid growth platform for our core business in Idaho Falls . We have a unique foundation of capabilities and a long history of working with the NRC in obtaining many amendments to our NRC license in order to support that business development and growth. Although our business is heavily regulated, which at times makes the progress slow, we are very excited by the products and businesses that we have been working on, some of which we have outlined here, and others which we will update shareholders on when they are a little further advanced . We believe there are significant opportunities in front of us and that we can continue to build a dynamic company in our core business segments. We greatly appreciate shareholders' patience as we methodically work to bring these products and new business opportunities to fruition."
About International Isotopes Inc. International Isotopes Inc. manufactures a full range of nuclear medicine calibration and reference standards, a variety of cobalt-60 products, provides a wide selection of radioisotopes and radiochemicals for medical devices, calibration, clinical research, and industrial applications, and provides radiological services including source installation/removal, and decommissioning various radiation units on a contract basis to clients.
International Isotopes Inc. Safe Harbor Statement Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements with respect to our ability to build additional business, the likelihood of success of future projects, the ability to collect payments under contracts for our products, the Company's ability to apply for and gain regulatory approval of new products, and the Company's ability to bring new business opportunities to fruition. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance or achievements of International Isotopes Inc. to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in International Isotopes Inc.'s filings with the Securities and Exchange Commission at www.sec.gov, including our Annual Report on Form 10-K for the year ended December 31, 2014 . Investors, potential investors, and other readers, are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and International Isotopes, Inc. undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
FOR MORE INFORMATION CONTACT:
David Drewitz Creative Options Communications Investor and Public Relations david@creativeoptionscommunications.com www.creativeoptionsmarketing.com Phone: 972-814-5723
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/international-isotopes-inc-provides-shareholders-with-an-update-on-new-opportunities-and-positive-developments-within-its-existing-business-segments-300067612.html
SOURCE International Isotopes Inc.
Piss poor IR, can't capture a market
INIS ~ interesting ,hmmmmmm http://finance.yahoo.com/news/international-isotopes-inc-announces-third-150000859.html
I wonder how long before this stock catches fire
Interesting INIS filing ,took a position.
On October 2, 2014, International Isotopes Inc. (the “Company”) entered into an Isotope and Technical Service Order Form with the U.S. Department of Energy (the “DOE”) for the irradiation of cobalt targets for the production of cobalt-60 (the “Agreement”). Pursuant to the Agreement, the Company will receive cobalt irradiation services in certain target positions at the DOE’s Advanced Test Reactor at the Idaho National Laboratory (the “ATR”) for the next 10 years at a fixed price for all cobalt material from the ATR, with an annual 5% escalation in price.
The term of the Agreement begins on October 1, 2014 and ends on September 30, 2024. The Company may terminate the Agreement at any time upon 180 days’ advanced written notice to the DOE. The DOE may terminate the Agreement upon failure of the Company to pay amounts due under the Agreement, if the Company no longer is licensed to receive cobalt-60, or if the DOE determines that termination of the Agreement is necessary for the national defense, security or environmental safety of the United States.
The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by the terms of the Agreement. The Company will file a copy of the Agreement as an exhibit to its Annual Report on Form 10-K for the fiscal year ending December 31, 2014.
INIS Entry into a Material Definitive Agreement.
On October 2, 2014, International Isotopes Inc. (the “Company”) entered into an Isotope and Technical Service Order Form with the U.S. Department of Energy (the “DOE”) for the irradiation of cobalt targets for the production of cobalt-60 (the “Agreement”). Pursuant to the Agreement, the Company will receive cobalt irradiation services in certain target positions at the DOE’s Advanced Test Reactor at the Idaho National Laboratory (the “ATR”) for the next 10 years at a fixed price for all cobalt material from the ATR, with an annual 5% escalation in price.
The term of the Agreement begins on October 1, 2014 and ends on September 30, 2024. The Company may terminate the Agreement at any time upon 180 days’ advanced written notice to the DOE. The DOE may terminate the Agreement upon failure of the Company to pay amounts due under the Agreement, if the Company no longer is licensed to receive cobalt-60, or if the DOE determines that termination of the Agreement is necessary for the national defense, security or environmental safety of the United States.
The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by the terms of the Agreement. The Company will file a copy of the Agreement as an exhibit to its Annual Report on Form 10-K for the fiscal year ending December 31, 2014.
nope. the other way 'round. check the Form 4s filed 12/17. the insiders wanted to load up big time, but at a price they liked. only had a small starter position, but guess it's time to back up the truck when an insiders puts >10 mill shares into the kids' trust fund account...
Form 4's out on those buys just now...
Just doubled my money. Thank you.
Now back to 7 million shares traded. There where three "special" trades on level II close together for 9.0 million, 9.0 million and 9.47 million at 1:46 PM today and for a while it appeared that 34 million shares traded today.
Nice news today:
Friday, November 15 2013 9:30 AM, EST International Isotopes Inc. Announces Third Quarter And Nine Months 2013 Financial Results PR Newswire "Press Releases US - English"
IDAHO FALLS, Idaho , Nov. 15, 2013 /PRNewswire/ -- International Isotopes Inc. (OTC Bulletin Board: INIS) announces financial results for the third quarter and nine-months ended September 30 , 2013.
Company revenue for the three months ended September 30, 2013 was $1,680,696 , as compared to $1,793,483 for the same period in 2012, an overall decrease of $112,787 , or approximately 6%. Revenue for the nine-month period ended September 30, 2013 , was $5,153,534 , as compared to $5,785,775 for the same period in 2012, a decrease of $632,241 , or approximately 11%.
Revenue from the sale of radiochemical products for the three months ended September 30, 2013 was $450,285 , compared to $443,127 for the same period in 2012. This represents an increase in revenue of approximately 2%. Revenue from the sale of radiochemical products for the nine-month period ended September 30, 2013 , was $1,316,909 , compared to $1,230,161 for the same period in 2012. This is an increase in revenue of approximately 7%. This segment reported an increase of net income of 307% and 442% for the three and nine-month periods respectively. The increase in net income is the result of increased sales and reduced cost of sales through process efficiencies and enhancements.
Revenue from the sale of cobalt products for the three months ended September 30, 2013 was $332,295 , compared to $202,545 for the same period in 2012. This represents an increase in revenue of approximately 64%. Revenue from the sale of cobalt products for the nine-month period ended September 30, 2013 was $777,424 , compared to $1,035,975 for the same period in 2012. This represents a decrease in revenue of approximately 25%. The net income for cobalt products increased approximately 169% for the three months ended September 30, 2013 , but decreased by approximately 39% for the nine months ended September 30 , 2013. The increase in net income for the three-month period, is attributable to the increase in sealed source sales and the significant decrease in fees paid to the U.S. Department of Energy ("DOE") for certain cobalt production activities. The decrease in net income for the nine-month period was attributable to the reduced productivity resulting from the unavailability of cobalt material during most of this year due to technical issues with the cobalt target design.
Revenue from nuclear medicine products for the three months ended September 30, 2013 was $736,238 , compared to $1,021,230 for the same period in 2012. This represents a decrease in revenue of approximately 28%. Revenue from nuclear medicine products for the nine-month period ended September 30, 2013 was $2,455,987 compared to $3,223,359 for the same period in 2012, a decrease of approximately 24%. The decline in revenue in this segment, for both the three and nine-month periods was largely attributable to the decrease in sales reported by our joint venture, TI Services, LLC . TI Services, LLC sales for the three months ended September 30, 2013 , were $333,548 as compared to $554,380 , for the same period in 2012, a decrease of approximately 40%. TI Services, LLC sales for the nine months ended September 30, 2013 were $1,148,860 , compared to $1,857,678 for the same period in 2012, a decrease of approximately 38%. The decrease in TI Services, LLC sales is largely attributable to a drop in sales of paper products used in nuclear medicine imaging which is the result of clinics shifting towards maintaining electronic records. Despite the significant decline in revenue within this segment, cost controlling measures and production efficiencies have mostly sustained the segment's net income. Net income for this segment for the three and nine-month periods ended September 30, 2013 , decreased only about 3% and 1%, respectively, compared to the same periods in 2012.
Revenue from radiological services for the three months ended September 30, 2013 was $143,380 , compared to $64,006 for the same period in 2012, an increase of approximately 124%. Revenue for the nine-month period ended September 30, 2013 was $484,416 compared to $129,889 for the same period in 2012, and increase of approximately 273%. The majority of the increase in revenue within this segment is the result of increased field service activity. Net income for the three months ended September 30, 2013 declined about 61% compared to the same period in 2012, however, net income for the nine-month period increased by about 161%. The variability in revenue and net income in the period comparisons is attributable to the random nature of the field service work contracts. We anticipate net income within this segment to continue to improve for the remainder of 2013 and beyond as much of the initial costs related to launching the field services work will diminish.
Overall Company gross profit for the three months ended September 30, 2013 was $623,942 , compared to $626,507 for the same period in 2012. This represents a decrease of less than 1%. Cost of sales decreased to $1,056,754 for the three months ended September 30, 2013 from $1,166,976 for the same period in 2012, a decrease of approximately 9%. Gross profit for the nine-month period ended September 30, 2013 was $1,991,574 , compared to $1,954,200 , for the same period in 2012, an increase of approximately 2%.
Operating expenses decreased to $951,452 for the three months ended September 30, 2013 , from $1,187,554 for the same period in 2012. This is a decrease of approximately 20%. Operating expenses were $3,199,908 for the nine-month period ended September 30, 2013 , compared to $3,658,817 for the same period in 2012. This represents a decrease of approximately 13%. The reductions in operating expense are the result of management's continued efforts to reduce discretionary costs where possible and secure beneficial pricing on general operating purchases. Research and development expense incurred, with regard to the planning and construction of the proposed de-conversion facility we plan to build in New Mexico , decreased by approximately 48% and 29% for the three and nine months ended September 30, 2013 , respectively, compared to the same periods in 2012.
Our net loss for the three months ended September 30, 2013 was $424,107 , compared to $591,526 for the same period in 2012. This is a decrease in loss of approximately 28%. Our net loss for the nine-month period ended September 30, 2013 , was $1,492,209 as compared to $1,696,905 for the same period in 2012. This is a decrease in loss of approximately 12%. The decrease in net loss is the result of the slight increase in gross profit percentage as well as a significant reduction in overall operating costs and expenses.
Steve T. Laflin , President and CEO of the Company said, "Despite the small decline in revenue seen this year we have been able to successfully control production costs and reduce operating expenses in order to improve gross profit and continue to move the Company towards profitability. Part of that cost control involves placing additional engineering work and formal design activities for the planned Hobbs de-conversion facility on hold for the time being. We are still confident that we will eventually be able to obtain contracts for additional de-conversion service and once we have fully committed the capacity of the facility under contract we will once again resume our search for financing the balance of the project and resume the schedule for design and construction.
"Delays in cobalt production activities and transfers have had the most detrimental impact to our core business this year but we are now moving past those issues. We have been able to resume cobalt shipments of targets for processing and sale beginning in October and this will permit resumption of cobalt product sales in the last quarter of 2013 and the first two quarters of 2014. This should provide a significant boost to revenue in those periods and we are still making progress with the evaluations necessary to resume irradiation of our cobalt targets as well. More information on our ability to resume those cobalt target irradiations should be available at year end.
"Perhaps the most positive sign of our improving business performance can be seen in reviewing our segment net income. Total net income from all business segments improved from just $6,099 to $205,897 for the three-month period and from $42,783 to $362,974 for the nine-month period ended September 30, 2013 compared to the same periods in 2012. For the three-month period this increase in net income was led by increases in radiochemical and cobalt product segments and for the nine-month period the increase was driven by radiochemical products and radiological services. We expect to continue to improve our business segment net income performance in the last quarter of this year as well.
"The Company's other major initiative involves our proposal to operate the Paducah Gaseous Diffusion Plant (PGDP). The Company is working with Advanced Process Technology Systems LLC (APTS) to form a joint venture and has submitted a proposal to the DOE under a Request For Offers solicitation process. That proposal was provided to the DOE in August 2013 and the Company was invited to make an oral presentation and answer questions on the proposal in September 2013. There is no indication that the DOE will accept or respond favorably to this proposal, however, the DOE expects to announce a decision by the end of November 2013 . There are a number of factors that could limit the ability of the joint venture to obtain the DOE's acceptance or operate the PGDP, including, but not limited to, obtaining additional adequate financing to support the proposal. However, the Company believes it has submitted a unique proposal to the DOE that offers considerable advantage to the DOE and U.S. taxpayers and is expected to provide a significant financial return to the Company."
INIS .07 Nice Vol coming in. Stock has rebounded off of .06 2X in recent history.
~ $INIS ~ Parabolic SAR Buy Signals ~ Criteria alert for last trading session!
$INIS has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~
For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~
What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~
To find other similar posts of "INIS" utilize the links that follow.
Search FaStlane's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2011&SearchStr=ParSarBuyScan ~
Search FaStlane's posts for symbol "INIS": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2011&SearchStr=INIS ~
Search Ihub for "INIS" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=INIS ~
For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~
Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~
Someone selling through CANT....once they are done then we move...painful for now
Good volume of late, as well. I know someone is selling, but there seem to be buyers (bidders) at this level.
I can hold a few months here.
Oversold but seems to be selling pressure. Going to see triple bagger off the bottom.
$3,992,292 in Revenues for Six Months
Revenue for the three months ended June 30, 2012 was $2,042,949, as compared to $2,614,744 for the same period in 2011, an overall decrease of $571,795, or approximately 22%. Revenue for the six months ended June 30, 2012, was $3,992,292, as compared to $5,028,059 for the same period in 2011, a decrease of $1,035,767, or approximately 21%.
http://ih.advfn.com/p.php?pid=nmona&article=53836776
8/28/12
HOBBS NEWS SUN
FRONT PAGE ARTICLE
HEADLINE
"IMPACT REPORT CLEARS ISOTOPES,*NRC license set to be signed on Sept. 30th".................tick tick tick tick
Will INIS break the 50 Day?
Confidential Treatment Order (CT ORDER)
http://ih.advfn.com/p.php?pid=nmona&article=52466072
INIS Announces First Quarter 2012 Financial Results
IDAHO FALLS, Idaho, May 15, 2012 /PRNewswire/ -- International Isotopes Inc. (OTC Bulletin Board: INIS) announces financial results for the first quarter ended March 31, 2012.
Revenue for the three-month period ended March 31, 2012 was $1,949,343, as compared to $2,413,315 for the same period in 2011, an overall decrease of approximately 19%. While the Company reported a decline in revenue from all business segments for the period, the net loss for the three-month period ended March 31, 2012 was $590,247, compared to $1,715,012 for the same period in 2011, an improvement of nearly 66%, and is primarily due to the decrease in research and development expense related to the licensing and planning for the proposed de-conversion facility.
Cost of sales decreased to $1,278,603 for the three-month period ended March 31, 2012 from $1,494,278 for the same period in 2011 and was tied directly to the decrease in sales for the same period comparison. Gross profit for the three-month period ended March 31, 2012 was $670,740, compared to $919,037 for the same period in 2011, representing a decrease of approximately 4% in gross profit percentage of revenue.
The Company also reported a decrease in operating expenses for the period. Operating expense decreased to $1,276,935 for the three-month period ended March 31, 2012, from $2,496,886 for the same period in 2011, an overall decrease of approximately 49% which was primarily attributable to capitalizing certain research and development costs related to the planning, and licensing of the proposed de-conversion facility. The Company also noted that salaries and contract labor expense decreased by approximately 19% in the period comparisons as a result of a decrease in the amount of non-cash equity based compensation expense recorded for the three months ended March 31, 2012.
Steve T. Laflin, President and CEO of the Company said, "In spite of the decline in revenue of each business segment during the first quarter, I remain optimistic about overall business performance for the remainder of 2012. While it is unlikely that our revenue totals for 2012 will meet or exceed the levels in 2011, we still expect improving sales and financial performance for the remainder of the year in most segments. We expect to continue to expand upon international sales of our Nuclear Medicine products. We are finishing implementation of a wide range of Current Good Manufacturing Practice (CGMP) corrective actions and initiatives that should improve our marketing efforts of radiochemical products to regain historical sales levels in the segment. We anticipate strong sales in the cobalt products segment for the remainder of 2012 based on current customer commitments. We are seeing an improving trend in the volume of business expected in our Radiological Services segment that should translate into improved revenue in this segment later in the year. And lastly, the small loss reported by our joint venture, TI Services, LLC in the first quarter was the result of a prior year unrecorded expense correction that eliminated what would have otherwise been a small profit for the joint venture in the first quarter. While I expect revenue this year to remain below 2011 levels we expect to be able to continue to control costs and add some new business to help improve the overall margins with several segments for the rest of 2012."
"We also wish to report the Nuclear Regulatory Commission (NRC) continues to make progress on our license application review for the planned depleted uranium de-conversion and fluorine extraction processing facility. The most recent NRC website update on our license status indicates that the NRC expects to issue the final Safety Evaluation Report by about June 2012, the final Environmental Impact Statement by about September 2012, and issue our construction and 40 year operating license in October 2012. In parallel with this licensing process, work continues on the formal design of the facility. We expect to continue to incur capital costs associated with this project in 2012 based on our ability to raise funds to support it."
http://ih.advfn.com/p.php?pid=nmona&article=52418732
About International Isotopes Inc.
International Isotopes Inc. manufactures a full range of nuclear medicine calibration and reference standards, high purity fluoride gases, and a variety of cobalt-60 products such as teletherapy sources. The Company also provides a wide selection of radioisotopes and radiochemicals for medical devices, calibration, clinical research, life sciences, and industrial applications and provides a host of analytical, measurement, recycling, and processing services on a contract basis to clients
INIS Announces Nuclear Regulatory Commission Final Approval Of The Safety Evaluation Report
IDAHO FALLS, Idaho, May 31, 2012 /PRNewswire/ -- International Isotopes Inc. (OTC Bulletin Board: INIS) (The Company) is very pleased to announce that the U.S. Nuclear Regulatory Commission (NRC) has completed its review and approval of the final Safety Evaluation Report (SER) for the Company's planned depleted uranium de-conversion and fluorine extraction processing facility. The NRC has published the final SER as U.S. NRC Regulation (NUREG-2116) and has posted the document on the NRC website and published it in the Federal Register.
The Company originally submitted its license application to the NRC in December 2009, and the NRC has been reviewing that application and preparing the SER since that time. The SER documents the NRC's staff review and their evaluation of safety, and potential adverse impacts on workers and the public under both normal operations and accident conditions. The NRC review also considers the management organization, administrative programs, and financial qualifications provided by the Company to ensure safe design and operation of the facility. The NRC staff has concluded, in this SER, that the Company's descriptions, specifications, and analyses provide an adequate basis for safety of facility operations and that operation of the facility does not pose an undue risk to workers or public health and safety.
The NRC approval and publication of the SER is a major milestone in the licensing process for the Company's planned facility. The only remaining NRC action to be completed before the Company is issued its combined forty-year construction and operating licenses for the facility is the final Environmental Impact Statement (EIS), which is expected to be issued as a final document around September 2012.
Steve T. Laflin, President and CEO of the Company said, "The NRC approval of the SER is certainly a major milestone in the Company's effort to license and construct the first ever "green" depleted uranium de-conversion and fluorine extraction processing facility in the U.S. This is a truly unique, first of its kind facility, and the first SER to be issued by the NRC for a facility fully compliant with the NRC's new Part 40 requirements, which incorporate integrated safety analysis as part of the original facility design. I would like to recognize the NRC staff for their excellent coordination and communication with the Company throughout the document review process as well as NRC management who worked to ensure the review process was completed in a timely manner and close to the original review schedule. I would also like to recognize the outstanding work of our management staff and our licensing and engineering subcontractor, Advanced Process Technology Systems, for the preparation of a high quality application and diligent support of the NRC requests for additional information. The overall quality of the license application allowed the NRC review to proceed without major challenges or problems with the technical or safety basis aspects of the plant design and planned operation."
http://ih.advfn.com/p.php?pid=nmona&article=52621802
INIS ~ Green Uranium?.....A Must Read
Putting depleted uranium to good use is a surprisingly sustainable and economically valuable solution.
BY JIM THOMAS
In recent years, nuclear power has been getting a second look. The increased attention in nuclear energy has been stimulated of late through changes in governmental policy (i.e., loan guarantees), public opinion on global warming, concerns over foreign oil dependence and industrial investment opportunities.
The upswing in planned construction of domestic and international nuclear power facilities will certainly provide important environmental bene?ts. The most obvious bene?t being the large reduction in carbon dioxide emissions in comparison to coal or natural gas ?red power plants. Also, President Barack Obama recently has announced a goal of putting 1 million electric cars on U.S. roads by 2025. In order to realize the full environmental bene?t of that growing ?eet of electric vehicles, it also will be important that the electricity produced to power them be supplied by clean base load nuclear power.
Although nuclear energy production itself results in some of the lowest total carbon emissions compared to other energy production methods, critics of the industry are quick to point out two of nuclear’s major drawbacks, namely high cost of construction and high-level waste disposal. The nuclear industry counters the concern with high cost through plans to standardize design and carry out modular construction. The volume produced from decades of power production is quite small, and the interim storage measures used to contain and control this material have been – and will continue to be – adequate for another 100 years until a permanent solution is put in place.
Although debate is certain to continue on those issues, there is actually a potentially larger issue facing the nuclear industry – an issue that has not been adequately addressed, has seen little public attention, and yet may become the largest future issue facing the industry. That issue is the production of depleted uranium from the front end of the nuclear fuel cycle.
There is, however, a company planning to construct a facility in the United States that would not only solve this issue for the industry, it would do so in a manner that recovers valuable ?uoridebearing materials, produces important commercial products and saves energy in the process. That company is International Isotopes Inc. (INIS), and its process is called depleted uranium deconversion and ?uorine extraction.
Full article here http://www.intisoid.com/wp-content/uploads/2011/03/+URANIUM_ENERGY-MINING-TEMPLATE.pdf
INIS ~ Nuke Plant to Move Forward
An article from earlier this year about INIS's plans going forward.
http://www.intisoid.com/wp-content/uploads/2011/03/Nuke-Plant-to-Move-Forward.pdf
INIS ~ Products and Services
» Cobalt and Radiochemical Products
We bring the benefits of nuclear technology to a wide variety of medical and industrial applications. Our cobalt products are used by a broad array of companies for radiation treatment of cancer and vascular deformities of the brain. Cobalt sources are also used for container security examinations at our sea ports and borders. Our radiochemicals, such as Iodine-131, are used in medicine for treatment of a host of thyriod diseases and disorders.
» Nuclear Medicine Calibration Standards
Calibration standards are used for a range of applications in nuclear pharmacy from testing of imaging machines to calibration of patient dose measurement devices. These products help ensure that nuclear medicine pharmacies, procedures, and devices perform as intended to offer safe and effective patient treatment, therapy, or imaging. We are a contract manufacturer to RadQual LLC for many of these products. Please visit their website for more information.
» Transportation
We have partnered with Alpha Omega Services, Inc. to provide a one-stop solution for nuclear material transport services. We offer nuclear material transport casks for sale, lease or rent and are the exclusive worldwide distributor of the AOS Radioactive Material Transport Packaging System (NRC license pending). Our transportation services also specialize in providing safe, secure, and cost effective transport of all class 7 radioactive materials.
INIS On Track For NRC License In 2012
International Isotopes on Track For NRC License in 2012
By Dan Yurman, Contributing Reporter
Efforts to secure equity funding to build a $125 million uranium deconversion plant in Hobbs, New Mexico are gaining momentum even though the company announced on March 17 that it would pull a $31 million public stock offering. CEO Steve Laflin told FCW in an exclusive interview that debt financing would take the company most of the way toward its fundraising goal.
Laflin said the firm has applied for a $97 million loan from the U.S. Department of Energy, which approved the first of a two-part application last June. The loan comes from the department’s renewable-energy technology development program, which counts as a key factor for loan approval whether the technology reduces in greenhouse gas emissions.
“Our patented fluorine extraction process uses seven times less energy than conventional industrial processes for making hydrofluoric acid,” Laflin said. “This means we can show reductions of six million pounds of carbon dioxide a year over the life of the plant.”
Laflin expects the agency to issue a conditional commitment for the loan that will require that the firm secure an NRC license. The draft Safety Evaluation Report is to be done by late summer, and a final Environmental Impact Statement could be ready by yearend, depending on the outcome of the public comment process. Laflin would not say when he expected action on the second part of the loan-application process.
Article continues here http://www.intisoid.com/wp-content/uploads/2011/04/INIS_On_Track_For_NRC_License_In_2012.pdf
INIS ~ Q3 and Nine Months 2011 Results
International Isotopes Inc., announces financial results for the third quarter and nine-months ended September 30, 2011.
Revenue for the three-month period ended September 30, 2011 was $2,229,947, as compared to $1,783,047 for the same period in 2010, an overall increase of $446,900, or approximately 25%.
Revenue for the nine-month period ended September 30, 2011 was $7,258,006, as compared to $4,377,891 for the same period in 2010, an increase of $2,880,115, or approximately 66%.
All business segments reported increases in revenue for the nine-month period, and all segments, with the exception of the cobalt products segment, reported increases for the three-month period comparison. The cobalt product segment reported a decrease in revenue of $431,113 for the three-month period comparison but this decrease is due to there were no bulk cobalt sales for the three months ended September 30, 2011 whereas the Company reported $551,728 in bulk cobalt sales for this same period in 2010.
The Company's three most significant business segments are Radiochemical Products, Nuclear Medicine Standards, and Cobalt Products. Revenue from the sale of radiochemical products for the three-month period ended September 30, 2011 was $480,562 compared to $446,533 for the same period in 2010. This represents an increase of $34,029, or approximately 8%. Revenue from the sale of radiochemical products for the nine-month period ended September 30, 2011, was $1,397,763, compared to $1,295,193 for the same period in 2010. This represents an increase in revenue of $102,570, or approximately 8%. Increases in this segment's performance are attributable to increased sales of radiochemical iodine-131 which have remained strong for the three and nine-month periods.
Revenue from nuclear medicine products for the three-month period ended September 30, 2011, was $1,246,417, compared to $459,769 for the same period in 2010. This represents an increase in revenue attributable to this segment of $786,648, or approximately 171%. Revenue from nuclear medicine products for the nine-month period ended September 30, 2011 was $3,825,973, compared to $1,376,807 for the same period in 2010. This represents an increase in revenue attributable to this segment of $2,449,166, or approximately 178%. In December 2010, we entered into a 50/50 joint venture with RadQual, LLC and formed TI Services, LLC. Revenues generated by TI Services, LLC during the three and nine-month periods ending September 30, 2011 are being reported on a consolidated basis in our nuclear medicine business segment. Total revenue generated by TI Services, LLC for three-month period was $716,728 and for the nine months was $2,272,096.
Revenue from the sale of cobalt products for the three-month period ended September 30, 2011 was $401,745 compared to $832,858 for the same period in 2010. This represents a decrease in revenue of $431,113, or approximately 52%. Revenue from the sale of cobalt products for the nine-month period ended September 30, 2011 was $1,635,989, compared to $1,479,120 for the same period in 2010. This represents an increase in revenue of $156,869, or approximately 11%. The decrease in revenue from the sale of cobalt products for the three-month period as compared to the same periods in 2010 is largely the result of the timing of large bulk cobalt product sales that occurred during the periods, which have a dramatic effect on period-to-period comparisons.
Gross profit for the three-month period ended September 30, 2011 was $775,879, compared to $618,860 for the same period in 2010. This represents an increase of $157,019, or approximately 25%. Cost of sales increased to $1,454,068 for the three-month period ended September 30, 2011 from $1,164,187 for the same period in 2010. Cost of sales for the period ended September 30, 2011 includes $551,515 of cost of sales for TI Services, LLC, whereas there was no such expense reported for the same period in 2010. The overall increase of $289,881 is due to consolidated reporting of TI Services, LLC's cost of sales along with a total combined decrease of all other business segment's cost of sales. The gross profit percentage for the three months ended September 30, 2011 was 35%, which is unchanged from the same period in 2010.
Gross profit for the nine-month period ended September 30, 2011 was $2,694,137, compared to $1,731,461, for the same period in 2010. This represents an increase of $962,676, or approximately 56%. Gross profit for the nine-month period ended September 30, 2011 includes TI Services, LLC revenues in the amount of $2,272,096 and TI Services, LLC cost of sales in the amount of $1,786,246. The first year of reporting TI Services, LLC activity on a consolidated basis with all other business segments was 2011, therefore, there are no corresponding sales or cost of sales to report for TI Services, LLC in 2010.
Operating expenses increased to $3,237,630 for the three-month period ended September 30, 2011 from $2,239,548 for the same period in 2010, an increase of $998,082 or approximately 45%. This increase was attributable to recording of a $1,127,990 non-cash equity-based compensation expense related to outstanding stock options, the issuance of Class H Warrants, and a modification in the terms in all outstanding warrants in connection with a discounted warrant exercise offering made by us during the period. Research and development costs decreased by $229,682, or approximately 16% during this period as a result of economizing on funds spent on licensing and engineering design work being done for the planned uranium de-conversion facility.
Operating expenses were $8,283,997 for the nine-month period ended September 30, 2011, compared to $6,076,597 for the same period in 2010. This represents an increase of $2,207,400, or approximately 36%. This increase is again attributable to the significant amount of non-cash equity-based compensation in the amount of $1,429,839 recorded during the nine-month period ended September 30, 2011, as compared to the same period in 2010, in which we reported non-cash equity-based compensation in the amount of $593,847. Research and development costs generated by work related to the continued planning and licensing of the uranium de-conversion facility increased by $750,232 for the nine-month period ended September 30, 2011 to $4,238,229, as compared to $3,487,997 for the same period in 2010.
Our net loss for the three-month period ended September 30, 2011 was $4,869,604, compared to $1,764,385 for the same period in 2010. This is an increase in loss of $3,105,219, or approximately 176%, and is primarily attributable to reporting non-cash equity-based compensation expense and $2,372,143 in non-cash expense related to the maturity of convertible debentures, which were converted in October 2011. The debentures were converted at a per share price of $0.18 which was less than market value per share at the date the agreement was entered into in February 2010, and thus presented a beneficial conversion feature to holders of the debentures. The value of this beneficial feature was recorded as additional interest expense at the time of conversion.
Our net loss for the nine-month period ended September 30, 2011 was $8,254,802, as compared to $4,736,317 for the same period in 2010. This is an increase in loss of 3,518,485, or 74%, and was largely attributable to $2,372,143 of non-cash interest expense recorded upon the maturity of convertible debt which was incurred to support the on-going development of the depleted uranium project, to $591,238 of non-cash compensation expense related to the issuance of Class H Warrants, and to non-cash expense in the amount of $476,294 resulting from a discounted warrant exercise offering.
Steve T. Laflin, President and CEO of International Isotopes Inc. said, "The continued strong performance of our major business segments, coupled with the positive contribution of TI Services, LLC revenue, has made this the Company's strongest nine-month revenue performance in our operating history. I believe these trends in business revenue performance are likely to continue for the remainder of the year. I would also like to specifically call attention to the large amount of non-cash expense the Company has had to record during this recent quarter as the result of several transactions. The combined effect of the Class H warrant transaction, the discount warrant exercise, and completion of the convertible debenture transaction resulted in the Company recording a total of more than $3.4 million in non-cash equity-based compensation and interest expense. I wish to point out that most of these were one-time transactions all happened within a relatively short period of time and within a single quarterly reporting period. These non-cash expenses should be taken into consideration when evaluating the Company's overall financial performance for the three and nine month periods."
"The Company is also pleased to report continued progress on efforts related to our planned depleted uranium de-conversion and fluorine extraction processing facility. During the third quarter the Company made significant further progress towards the completion of the licensing for the facility with the Nuclear Regulatory Commission (NRC), completed the selection of the design and build contractor for the project, and completed the title transfer for acquisition of the real property for the facility in Lea County New Mexico. We continue to anticipate the NRC license review to be completed by June 2012. Overall, the project is progressing quite well but, as we have noted in the past, our ability to successfully complete the licensing, design, and construction of this project will require substantial additional funding. We will continue to manage our expenditures on this project and utilize the cash produced from our core business segments to sustain our operations and support budgeted work on the planned project until such time that market conditions for further debt or equity financing improve."
http://ih.advfn.com/p.php?pid=nmona&article=49955613
INIS International Isotopes Inc Interview CEO Steve T. Laflin Nov 11,2010 at PM EST http://bit.ly/9jVOez
$INIS International Isotopes Inc Interview CEO Steve T. Laflin Nov 11,2010 at PM EST http://bit.ly/9jVOez
Followers
|
16
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
187
|
Created
|
01/15/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |